Core Viewpoint - Maiwei Biotech announced that its adalimumab injection 9MW0113 (domestic brand name: Junmaikang®) has received registration approval from the Indonesian Food and Drug Authority (BPOM), marking it as the first adalimumab biosimilar independently developed in China to gain such approval in Indonesia [1] Group 1 - 9MW0113 was co-developed by Maiwei Biotech and Junshi Bioscience [1] - The product has been formally partnered in over ten countries, indicating a strong international collaboration strategy [1] - Registration application documents have been submitted to multiple countries, including Jordan and Peru, showcasing the company's global expansion efforts [1]

Group 1 - The core viewpoint of the articles highlights the significant interest from brokerages in A-share listed companies, with over 2800 companies receiving brokerage research in 2025, indicating that more than half of the market's listed companies have been under brokerage attention [1][2] - The mechanical equipment, electronics, and pharmaceutical biotechnology sectors are identified as the most favored by brokerages, with over 290 companies in each sector receiving research attention [1][2] - The mechanical equipment sector is particularly noted for investment opportunities in the humanoid robot industry chain, while the electronics sector is advised to focus on new technologies and demands driven by the AI innovation cycle [3][4] Group 2 - Crystal Optoelectronics, a company in the electronics sector, has been the most favored by brokerages, receiving 175 research visits, and is part of a sector that has seen a significant price increase of nearly 42% in 2025 [1][2] - The electronics sector has over 320 companies receiving brokerage research, with notable companies like Huaqin Technology and Luxshare Precision receiving more than 140 research visits each [2] - The pharmaceutical biotechnology sector has 296 companies under brokerage research, with a cumulative increase of only 12.44% in 2025, indicating a relative underperformance compared to other sectors [3][4] Group 3 - Investment opportunities in the humanoid robot sector are expected to grow, with a focus on companies entering the Tesla supply chain and those involved in core supply chain and standardization [3] - The electronics sector is anticipated to benefit from the AI-driven demand for high-performance storage and semiconductor testing equipment, suggesting a favorable outlook for related companies [4] - The pharmaceutical sector is expected to continue focusing on innovative drug companies, supported by favorable policies and increasing international market presence, which will attract more investor attention [4]

Group 1 - The core investment theme for the pharmaceutical sector in 2026 is the innovation drug industry chain, with a clear trend towards international business development and accelerated commercialization of domestic products [2][3]. - The CXO sector is experiencing continuous improvement in performance and orders, supported by favorable financing conditions that benefit the industry's upward trajectory [3]. - The medical device sector is focusing on two main lines: international expansion and innovation [3]. Group 2 - The latest trends in medical insurance show a decline in total expenditure for the first ten months of 2025, amounting to 1,903.6 billion yuan, a year-on-year decrease of 1% [5][7]. - The total income of the medical insurance fund for the same period reached 2,352 billion yuan, with a year-on-year growth of 2%, indicating a slowdown in income growth [7][11]. - The number of medical insurance beneficiaries and hospitalization cases continues to grow, with 6.07 billion total beneficiaries in 2024, a year-on-year increase of 18% [11]. Group 3 - The average medical insurance cost per visit decreased in 2024, with the average cost for employees at 629 yuan (down 10%) and for residents at 351 yuan (down 12%) [15]. - The average hospitalization cost also saw a decline, with employees averaging 11,707 yuan (down 3.8%) and residents at 7,408 yuan (down 3.5%) [15]. Group 4 - The Chinese pharmaceutical industry is witnessing a significant increase in license-out transactions, with over 100 deals completed in 2025, totaling more than 110 billion USD [21][32]. - The number of license-out transactions involving upfront payments exceeding 100 million USD has also risen, indicating a growing interest from global pharmaceutical companies in Chinese innovations [21][32]. - The ADC (Antibody-Drug Conjugate) market is expanding rapidly, with a projected market size exceeding 16 billion USD in 2025, driven by several successful product launches [38]. Group 5 - The Chinese government is actively supporting the innovation drug sector through various policies aimed at enhancing accessibility and encouraging high-quality innovation [16][18]. - The proportion of medical insurance spending on innovative drugs is steadily increasing, with 149 innovative drugs included in the insurance coverage over the past seven years [90][94]. - The average price reduction for innovative drugs during negotiations with the national medical insurance has been around 60%, with some drugs seeing reductions as high as 94% [88][94].

Core Viewpoint - The announcements detail the resolutions passed during the third extraordinary general meeting of shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd., including governance structure adjustments and the election of a new employee representative director [1][7]. Meeting Details - The meeting was held on December 25, 2025, with all 9 current directors and 3 supervisors present, along with the board secretary and legal witnesses [2][3]. - Voting was conducted through a combination of on-site and online methods, complying with the Company Law and the company's articles of association [2]. Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendments to the company's articles of association and related rules [3]. - Revision of corporate governance systems, including: - Independent director work system [3]. - Related party transaction management system [4]. - External investment management system [4]. - External guarantee management system [4]. - Fundraising management system [4]. - Director and senior management compensation management system [4]. - Implementation details for online voting at shareholder meetings [4]. - The special resolution regarding the cancellation of the supervisory board received over two-thirds approval, while the ordinary resolution on governance systems received over half approval from the voting shareholders [4]. Legal Witnessing - The meeting was witnessed by Beijing Zhide (Shanghai) Law Firm, confirming that the meeting's procedures and voting methods complied with relevant laws and regulations [6]. Director Resignation and Election - Non-independent director Gui Xun submitted a resignation report due to governance structure adjustments but will continue in other roles within the company [8]. - Gui Xun was elected as an employee representative director during the first session of the sixth member representative conference of the labor union, maintaining the board's compliance with legal requirements [8][10]. - The board remains at 9 members, with the number of directors who are also senior management not exceeding half of the total board [10].

证券代码：688062 证券简称：迈威生物 公告编号：2025-080 迈威（上海）生物科技股份有限公司 关于非独立董事辞任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 迈威（上海）生物科技股份有限公司（以下简称"公司"）董事会于 2025 年 12 月 25 日收到非独立董事桂勋先生的书面辞任报告，因公司治理结构调整， 桂勋先生申请辞去第二届董事会非独立董事职务。除辞任非独立董事职务外，桂 勋先生在公司担任的其他职务不变。 公司于 2025 年 12 月 25 日召开第一届工会委员会第六次会员代表大会暨 职工代表大会，同意选举桂勋先生为第二届董事会职工代表董事，与其他在任董 事共同组成公司第二届董事会。任期自本次会员代表大会选举之日起至公司第二 届董事会任期届满之日止。 1 板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规 范运作》等法律法规、规范性文件的相关规定。 一、董事离任情况 （一）提前离任的基本情况 | 姓名 | 离任 | 离任时间 | | ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-079 迈威（上海）生物科技股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 12 月 25 日 （二） 股东大会召开的地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 151 | | --- | --- | | 普通股股东人数 | 151 | | 2、出席会议的股东所持有的表决权数量 | 205,835,818 | | 普通股股东所持有表决权数量 | 205,835,818 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.5104 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 植德沪（会）字[2025]0058 号 二〇二五年十二月 上海市徐汇区虹桥路 183 号徐家汇中心三期 A 座办公楼 27 层（THREE itc） 邮编：200030 27th Floor Tower A, THREE itc, No.183 Hongqiao Road, Xuhui District, Shanghai 200030 P.R.C 电话(Tel)：021-52533500 传真(Fax)：021-52533599 www.meritsandtree.com 北京植德（上海）律师事务所 关于迈威（上海）生物科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 植德沪（会）字[2025]0058 号 致：迈威（上海）生物科技股份有限公司（贵公司） 本所律师参加本次会议进行见证，并根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理 ...

Group 1 - The core viewpoint of the news is that Maiwei Biotechnology has shown significant trading activity and financial performance, with a notable increase in revenue and changes in shareholder composition [1][2]. Group 2 - On December 24, Maiwei Biotechnology's stock rose by 0.99%, with a trading volume of 214 million yuan. The financing buy-in amount was 16.18 million yuan, while the financing repayment was 13.98 million yuan, resulting in a net financing buy-in of 2.20 million yuan. The total financing and securities balance reached 552 million yuan [1]. - The financing balance of Maiwei Biotechnology is 552 million yuan, accounting for 6.79% of its market capitalization, which is above the 60th percentile level over the past year, indicating a high level of financing [1]. - On the same day, the company had no shares repaid in securities lending, with 200 shares sold, amounting to 7,968 yuan. The securities lending balance was 325,600 yuan, which is below the 30th percentile level over the past year, indicating a low level of securities lending [1]. - As of September 30, the number of shareholders of Maiwei Biotechnology was 19,600, an increase of 9.15% from the previous period. The average circulating shares per person decreased by 8.38% to 10,425 shares [2]. - For the period from January to September 2025, Maiwei Biotechnology achieved operating revenue of 566 million yuan, a year-on-year increase of 301.03%. However, the net profit attributable to the parent company was -598 million yuan, reflecting a year-on-year increase of 13.89% [2]. - Among the top ten circulating shareholders as of September 30, 2025, E Fund Medical Healthcare Industry Mixed A ranked as the fourth largest shareholder with 3.17 million shares, marking a new entry. Hong Kong Central Clearing Limited ranked sixth with 2.87 million shares, a decrease of 1.87 million shares from the previous period. Southern CSI 1000 ETF ranked ninth with 2.19 million shares, also a new entry [2].

Core Viewpoint - Maiwei Biotech announced that it received a Clinical Study Continuation Notification from the FDA, allowing the clinical research of 9MW1911 to proceed as planned, focusing on its pharmacokinetics, safety, tolerability, and preliminary efficacy in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) participants [1] Group 1 - The FDA has approved the continuation of the clinical study for 9MW1911, which is a randomized, double-blind, placebo-controlled Phase IIa clinical trial [1] - 9MW1911 is an innovative monoclonal antibody developed based on a high-efficiency B lymphocyte screening platform, classified as a Class I therapeutic biological product [1] - The drug targets the ST2 receptor to block the IL33/ST2 signaling pathway and is currently advancing rapidly in Phase II clinical research in China, having completed the Phase IIa clinical study in COPD patients [1]

Core Viewpoint - Maiwei Biotech (688062.SH) has completed a share buyback, acquiring a total of 1,192,369 shares, which represents 0.30% of the company's total share capital [1] Summary by Categories Share Buyback Details - The maximum buyback price was 58.02 CNY per share, while the minimum price was 37.48 CNY per share [1] - The average buyback price was 41.93 CNY per share [1] - The total amount of funds used for the buyback was 49.9945 million CNY, excluding transaction fees such as stamp duty and commission [1]